Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Washington, D.C., Feb. 01, 2026 (GLOBE NEWSWIRE) -- Rare disease patients often have to make 17 medical visits before a diagnosis. Under the theme of Early Detection Drives Direction, Global Liver...
-
South San Francisco, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- The California Institute for Regenerative Medicine (CIRM) has approved a new funding program to accelerate therapies for rare diseases,...
-
SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
-
Seamless Therapeutics announces research collaboration and licensing agreement with Eli Lilly for gene therapy for genetic hearing disorders
-
Avance Clinical will meet biotech sponsors at Biotech Showcase 2026 in San Francisco, highlighting the launch of the new Early Phase Center of Excellence.
-
AUSTIN, Texas, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioMedWire: Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system,...
-
SAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
-
– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics – – Completed $60.3 million oversubscribed private placement led by Samsara...
-
Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolioC3 glomerulopathy (C3G)...
-
The financing supports Eliksa’s clinical development of ELK-003, a biological eye drop for ocular complications in Epidermolysis bullosa (EB) patients.The ongoing pilot study in cooperation with DEBRA...